FOXO Technologies Secures Majority Control of Ludwig
The company gains control of a diagnostic platform as it works to meet Nasdaq listing requirements within four months.
Updated on Oct. 29, 2026 in Healthcare
Live Poll
Do you trust that mergers between biotech companies will result in better health outcomes for patients?
FOXO Technologies Inc. has entered into agreements to acquire preferred stock and debt in Ludwig Enterprises, Inc., granting it majority voting control. The acquisition aims to integrate Ludwig’s pre-commercial genetic biomarker technology into FOXO’s existing healthcare portfolio.
Why it matters
The deal signals an attempt by FOXO to expand its technical capabilities by absorbing a developer of non-invasive diagnostics. Operators should watch for the closure of this deal as a bellwether for how firms consolidate early-stage biotech assets to diversify healthcare revenue streams.
The acquisition terms include a 120-day window to complete required Nasdaq listing and financing milestones. This transaction follows FOXO's established operational footprint, which includes subsidiary facilities in East Tennessee.
The players
FOXO Technologies Inc.
A healthcare company headquartered in West Palm Beach, FL, focused on scaling specialized clinical and diagnostic business units.
Ludwig Enterprises, Inc.
A Nevada-incorporated firm that owns non-invasive genetic diagnostic technology currently awaiting commercial status.
Thomas E. Terwilliger
A debt holder who entered into an agreement to sell his interest in Ludwig Enterprises notes to FOXO Technologies.
The details
FOXO Technologies is gaining majority voting power through stock purchase agreements and the acquisition of debt previously held by Thomas E. Terwilliger. The primary asset involved is Ludwig's Revealia platform, a non-invasive buccal swab technology designed to detect genetic markers of inflammation. Because Revealia lacks FDA clearance and commercial status, the deal effectively functions as an investment in speculative diagnostic R&D that FOXO intends to scale.
Timeline
October 29, 2026: FOXO announced the signing of stock and note purchase agreements.
120 days from signing: Deadline to secure Nasdaq listing approval and complete necessary financing.
Market Landscape
This move reflects a broader trend of mid-cap healthcare firms acquiring early-stage diagnostic assets to build out service lines. It follows the pattern of consolidation where companies leverage SEC-regulated structures to bring unproven technologies like Ludwig's Revealia under larger operational umbrellas.
Operators in the diagnostic space should monitor the integration of the Revealia platform, specifically looking for regulatory filing updates regarding FDA status. The 120-day clock on this deal provides a clear horizon for when market participants can expect to see if the technology moves toward commercialization.
The takeaway
FOXO's acquisition underscores a strategic push to gain control of pre-commercial diagnostic tools via leveraged asset purchase. Management teams looking at similar expansion paths should audit the FDA clearance status of all intellectual property targets before assuming their immediate viability in a service portfolio.
What happens next
The transaction completion remains contingent on Nasdaq listing approval and financing, which must conclude within 120 days of the October 29, 2026, announcement.
Further reading
For broader trends in medical diagnostics, visit the Healthcare section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust that mergers between biotech companies will result in better health outcomes for patients?
